Announcements Trials
Browse Landscape

Phase

Phase 3 12Phase 2 8Phase 4 3Phase 2/3 1

Status

Withdrawn 1Unknown 1Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Breast Carcinoma In Situ 1

Interventions

Dexamethasone 56Metformin 50Cyclophosphamide 47Saline Solution 39Cytarabine 37Cisplatin 36Zoledronic Acid 34Letrozole 34Carboplatin 33Sodium Chloride 32Bupivacaine 31Docetaxel 30Bevacizumab 30Vincristine 29Methotrexate 29Fluorouracil 28Propofol 27Capecitabine 27Fentanyl 26Doxorubicin 26Rituximab 25Drug Therapy 25Dexmedetomidine 25Prednisone 23Paclitaxel 23Oxaliplatin 21Morphine 21Gemcitabine 21Radiotherapy 19Prednisolone 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 4 × Toremifene × Clear all
NCT02344940 2019-09-24

TTOS

Shanghai Jiao Tong University School of Medicine

Phase 4 Completed
104 enrolled
Breast

Breast Neoplasms

NCT03238703 2018-12-27

Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer

Fred Hutchinson Cancer Center

Phase 4 Withdrawn
Breast

Breast Carcinoma In Situ, Breast Neoplasms

NCT02089854 2016-12-02

AETNBC

Peking Union Medical College Hospital

Phase 4 Unknown
800 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡